DossierENTITY

chemotherapy-resistant ovarian cancer

Coverage of chemotherapy-resistant ovarian cancer in the Nexus archive.

Earliest in view: Jun 3 · 23:01 UTCMost recent: Jun 3 · 23:01 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 3 · 23:01 UTCTHE GUARDIAN WORLD
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
NHS England approved Elahere, the first new drug for chemotherapy-resistant ovarian cancer in over 20 years, offering life-prolonging treatment to hundreds of women. Ovarian cancer affects over 300,000 women annually, with most diagnosed at advanced stages.